© 2005 Foundation for Promotion of Cancer Research
Multipoint Oncology Teleconference, Japan |
Multipoint Oncology Teleconference, Japan
This teleconference has been held on a weekly basis (on Thursday evenings) as a good opportunity for the discussion of important issues in clinical oncology. Nowadays, this plenary meeting among the major cancer centers is indispensable for maintaining the high standard of quality of cancer clinics throughout Japan.
Review (November, 2004)
November 4: Treatment-resistant cervical cancer (moderated by Dr Tanaka, Chiba Cancer Center, Chiba). The prognosis of treatment-resistant cervical cancers, such as bulky mass and cervical adenocarcinoma, remains poor despite improved therapeutic approaches. Dr Hatano (Chiba Cancer Center) reported on the efficacy of image guided radiation therapy (IGRT), in which gross tumor volume was determined by MRI. Dr Utsuki (Cancer Institute Hospital) showed the results of neoadjuvant chemotherapy for 21 cases of reluctant cervical cancer. A response rate of 57% and 9 cases of long-term survival after complete resection were reported. Dr Ohno (National Institute of Radiological Sciences) showed the indications of ionizing particle beam radiation therapy in 25 patients with cervical cancer, in which the 4-year survival rate was 55%.
November 11: Mutation of EGFR gene and treatment with gefitinib for lung cancer (moderated by Dr Mitusdomi, Aichi Cancer Center, Aichi). Very recently, the close correlation between the mutation of the EGFR gene in adenocarcinoma of the lung and the higher response to gefitinib was reported. Dr Kohsaka (Aichi Cancer Center) analyzed 59 patients who were given gefitinib after recurrence of tumor, and found that 40% had a mutation in the EGFR gene. The mutation was correlated with female gender, non-smoking history, and adenocarcinoma histology. Dr Yatabe (Aichi Cancer Center) reported the histologic characteristics of adenocarcinoma with EGFR gene mutations. Dr Yamamoto (Shizuoka Cancer Center) showed the forthcoming clinical trial with gefitinib based on the survey of mutation in the EGFR gene.
November 18: The improvement of outcome in colorectal carcinoma (moderated by Dr Ikeda, Yamagata Cancer Center, Yamagata). The improvement of therapeutic results in colorectal carcinoma is being attempted. Dr Sato (Yamagata Chuo Hospital) analyzed the prognostic impact of lateral dissection in 437 cases of advanced rectal carcinoma. Dr Yamauchi (Yamagata Chuo Hospital) discussed the indication of hepatic resection for liver metastasis from colorectal cancer. Analyzing 173 cases, a 5-year survival rate of 33.5% was shown. Dr Sadahiro (Tokai University) reported the randomized trial of arterial infusion therapy to control liver metastasis in stage II/III colorectal cancer. Patients were randomly assigned to infusion therapy or no therapy. A significantly better disease-free survival was demonstrated.
November 25: Giant cell tumor of the bone (moderated by Dr Murakami, Miyagi Cancer Center, Miyagi). Despite the histologic benignity of giant cell tumor of the bone, local recurrence and lung metastasis are known. Various attempts have been tried to alleviate metastasis. Dr Hosaka (Tohoku University) reported on 5 and 6 cases of local recurrence and lung metastasis, respectively. In the cases with long-term survival, spontaneous regression was also noted. Dr Murakami (Miyagi Cancer Center) reported the modes of standard treatment such as curettage with thermal cauterization, and chemical cauterization. The prognostic impact of adjuvant therapy is yet to be determined. Dr Hatori (Tohoku University) reported on in situ pasteurization and alcohol cauterization followed by bone grafting after curettage as adjuvant therapy.
For Japanese readers, detailed information of the conferences, including videos and slides of the presentations are available at http://kit.ncc.go.jp/
Institutions networked by a multipoint teleconference system: Sapporo National Hospital, Aomori Prefectural Central Hospital, Iwate Prefectural Central Hospital, Miyagi Cancer Center, Niigata Cancer Center, Tochigi Cancer Center, National Cancer Center, East, National Cancer Center, Chiba Cancer Center, Saitama Cancer Center, Aichi Cancer Center, Kure National Hospital, National Shikoku Cancer Center, National Kyusyu Cancer Center.
|
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||